Bausch + Lomb acquires Trukera Medical
Click Here to Manage Email Alerts
Bausch + Lomb has acquired Trukera Medical in an effort to expand its position in dry eye care, according to a press release.
Bausch’s announcement highlighted Trukera’s ScoutPro device, which is designed to measure osmolarity.
“As a global leader in dry eye disease management, as well as cataract and refractive medical devices and implants, we’re uniquely positioned to optimize presurgical preparation to help ensure positive postsurgical outcomes,” Luc Bonnefoy, president of surgical at Bausch + Lomb, said in the release. “ScoutPro has already become a valuable preoperative diagnostic tool for many U.S. surgeons, and with our scale, we believe it can have an even greater impact.”
Trukera, founded in 2009 and previously known as TearLab, launched ScoutPro in 2022.
“Premium outcomes today are increasingly measured by an ability to deliver both the refractive target and a high quality of vision for each patient,” Adam Szaronos, CEO and president of Trukera, said in the release. “Since hyperosmolarity is known to have a significant negative impact on quality of vision and patient satisfaction after cataract surgery, having an easy-to-use diagnostic tool can help surgeons meet their patients’ increasingly high expectations. By joining a global leader like Bausch + Lomb, we are excited to get this valuable tool in the hands of more surgeons to benefit more patients.”
Details of the acquisition were not disclosed.
Read more about
Click Here to Manage Email Alerts